Evidence about the treatment of hospitalized type 2 diabetes patients with incretin-based therapy has emerged in the past 15 years. Based on this evidence, dipeptidyl peptidase-4 inhibitors should be considered for hospitalized patients with type 2 diabetes and an algorithm for this is proposed. In relation to use of glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonist, further research is required to help define their role in the inpatient setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078129 | PMC |
| http://dx.doi.org/10.1111/jdi.13130 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.
Pharmaceuticals (Basel)
December 2024
Department of Endocrinology and Metabolism, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing 100044, China.
Type 2 diabetes and weight loss are associated with detrimental skeletal health. Incretin-based therapies (GLP-1 receptor agonists, and dual GIP/GLP-1 receptor agonists) are used clinically to treat diabetes and obesity. The potential effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice remain uncertain.
View Article and Find Full Text PDFThe growing range of complications of diabetes mellitus.
Trends Endocrinol Metab
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously under-recognised complications associated with T2DM are becoming more evident. The most common of these emerging complications are metabolic dysfunction-associated steatotic liver disease (MASLD), cancer, dementia, sarcopenia, and frailty, as well as other conditions involving the lung, heart, and intestinal tract. Likely causative factors are chronic inflammation and insulin resistance, whereas blood glucose levels appear to play a lesser role.
View Article and Find Full Text PDFThe Role of Exercise in Steatotic Liver Diseases: An Updated Perspective.
Liver Int
January 2025
Depatrtment of Medicine, Karsh Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), parallels the rise in sedentary lifestyles. MASLD is the most common form of steatotic liver disease (SLD), which represents the umbrella beneath which the vast majority of chronic liver diseases fall, including alcohol-related liver disease and their overlap. These conditions are the leading contributors to chronic liver disease, significantly impacting global morbidity and mortality.
View Article and Find Full Text PDFDecoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients.
Mayo Clin Proc
January 2025
Department of Surgery, Mayo Clinic, Jacksonville, FL.
Incretin-based obesity management medications (OMMs) fill a treatment gap in a stepped-care model between lifestyle change alone and metabolic bariatric surgery, resulting in weight loss of 15% to 20% of body weight. Public interest in and demand for OMMs has recently increased dramatically. Unfortunately, cost and access to OMMs remain a significant barrier for many patients.
View Article and Find Full Text PDFIncretin-based therapy: a new horizon in diabetes management.
J Diabetes Metab Disord
December 2024
Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Diabetes mellitus, a metabolic syndrome characterized by hyperglycemia and insulin dysfunction, often leads to serious complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease. Incretins, gut peptide hormones released post-nutrient intake, have shown promising therapeutic effects on these complications due to their wide-ranging biological impacts on various body systems. This review focuses on the role of incretin-based therapies, particularly Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, in managing diabetes and its complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!